Igualada

This work is a clinical trial of randomized and controlled groups. The hypothesis of study is that BBAT applied in patients with fibromyalgia improves, more than stretching exercises, the pain, normalization biomarkers, improve in psychological state and quality life. The study population will be selected followed the inclusion criteria of fibromyalgia, and will be selected in Consorci Sociosanitari of Anoia, the patients will be divided in 2 groups, control and treatment group. The groups will be examined at the begin, at 2 weeks, at the end of treatment and 3, 6 and 12 months follow-up. The dependence measurements will be biomarkers serotonin, dopamine and cortisol, also Visual Analog Scale, State Trait Anxiety Inventory (STAI A/R), Beck Depression Inventory (BDI-II) and Fibromyalgia Impact Questionnaire (FIQ). The independence measurements will be demographic items: sex, age, country, level of studies, social status...

Researchers are evaluating whether ultrasound-guided alcohol sclerotherapy can reduce pelvic pain and improve quality of life in women aged 18 to 45 diagnosed with ovarian endometriomas. This condition involves abnormal growth of endometrial tissue outside the uterus and can cause chronic pelvic pain and infertility. The study compares sclerotherapy to expectant management to see which approach better improves pain and quality of life using the EHP-5 score. Participants will be randomly assigned to either the sclerotherapy group, which undergoes ultrasound-guided puncture and alcohol injection, or the control group, which receives expectant management without intervention. The study focuses on evaluating pain relief, quality of life, pregnancy rates, recurrence, adverse events, and treatment costs over six months. During the study, participants will complete pain and quality of life assessments at the start and after six months. They will also provide blood and urine samples for biomarker analysis and have ovarian reserve tests. Researchers will monitor safety, recurrence of endometriomas, fertility outcomes, and cost-effectiveness. The goal is to understand the benefits and risks of sclerotherapy compared to no treatment over this time period.